# Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

> **NCT07518602** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 34 (estimated)

## Conditions studied

- Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07518602
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2028-03-27
- **Final completion:** 2028-09-27
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07518602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07518602, "Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07518602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*